Refractory Chronic Lymphocytic Leukemia (CLL) is an indication for drug development with over 140 pipeline drugs currently active. According to GlobalData, preregistered drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 71.43% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Refractory Chronic Lymphocytic Leukemia (CLL) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Refractory Chronic Lymphocytic Leukemia (CLL) overview
Refractory chronic lymphocytic leukemia (CLL) signifies resistance to standard treatments or rapid relapse following initial therapy. This form of blood and bone marrow cancer presents a formidable challenge, as conventional chemotherapy and targeted approaches may prove ineffective. Managing refractory CLL involves exploring novel agents, immunotherapy, and participation in clinical trials to identify alternative treatment avenues. Tailoring therapy to the unique characteristics of the CLL cells and the patient’s overall health is crucial. Prognosis varies, highlighting the need for ongoing research to develop more efficacious treatments and improve outcomes for individuals grappling with refractory CLL.
For a complete picture of PTSR and LoA scores for drugs in Refractory Chronic Lymphocytic Leukemia (CLL), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
